December 18, 2017 / 2:20 PM / 6 months ago

BRIEF-Novartis Multiple Sclerosis Therapy Fingolimod Granted FDA Breakthrough Therapy Designation For Pediatric MS

Dec 18 (Reuters) - Novartis Ag:

* NOVARTIS MULTIPLE SCLEROSIS THERAPY FINGOLIMOD GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION FOR PEDIATRIC MS

* NOVARTIS- U.S. FDA GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR FINGOLIMOD FOR TREATMENT OF CHILDREN, ADOLESCENTS 10 YEARS OR OLDER WITH RELAPSING MS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below